Media Inquiries

If you are interested in interviewing a CCR scientist, OR you are a scientist who has been contacted by a member of the media, please contact the NCI Press Office at ncipressofficers@mail.nih.gov or by phone at 240.760.6600.

News and Events

engineered natural killer cells (yellow) can expand in solid tumors and kill tumor cells (red)

Stem cell–derived natural killer cells engineered to attack solid tumors

Cancer-killing natural killer cells could pave the way to off-the-shelf immunotherapy for solid tumors.

Drug shrinks nerve tumors in adults with neurofibromatosis type 1 in a clinical trial

Until recently, no effective treatments existed for non-cancerous inoperable nerve tumors, called plexiform neurofibroma, in adults. A clinical trial of the drug selumetinib shows it can cause tumor shrinkage and relieve symptoms, such as pain.

Celebrating CCR Careers: Jay A. Berzofsky, M.D., Ph.D.

Jay A. Berzofsky, M.D., Ph.D., a chemist-turned-immunologist who pioneered cancer immunology and immunotherapy strategies, announces his retirement from the NCI.

Empowering others to contribute to rare neuroendocrine tumor research

Lacey Koelling was diagnosed with paraganglioma tumors in 2018, which began to metastasize five years later. She enrolled in an NIH trial to contribute to research on this rare cancer.

An observant patient opens new doors for cancer screening

David Drash enrolled in a CCR clinical trial when he was diagnosed with BAP1 tumor predisposition syndrome (TPDS) in 2022. He noticed that everyone in his family with BAP1 TPDS had white lines on their fingernails; his observation led to the discovery of a new detection tool.

Celebrating CCR Careers: Alan Rein, Ph.D.

Alan Rein, Ph.D., is a known expert in the field of viral assembly, particularly in retroviruses like the human immunodeficiency virus (HIV). After an extensive career studying molecular mechanisms of retroviral replication and pathogenesis, he has announced his retirement.